

Cerebrotech Visor receives FDA nod

05 January 2018 | News

The Visor is a noninvasive bioimpedance spectroscopy device that detects changes and distribution of cerebral fluids



Clearance of a simple, easy-to-use device that can provide accurate information about cerebral fluids in 30 seconds is an important development

Cerebrotech Medical Systems is a venture capital-backed company dedicated to designing neurotechnology solutions to improve the care of brain-injured patients worldwide.

For the Cerebrotech Visor, previously known as the CMS-5000 Intracranial Fluids Monitor the company has received clearance from the Food and Drug Administration,

The clearance includes a broad indication for use as an aid in the assessment of fluid volume differences between the cerebral hemispheres in patients undergoing neurologic assessment.

The company is continuing its clinical studies to further validate the device for identifying specific brain pathologies including stroke, trauma, swelling and others.

The Visor is a noninvasive bioimpedance spectroscopy device that detects changes and distribution of cerebral fluids using its proprietary technology called Volumetric Impedance Phase-shift Spectroscopy (VIPS™).

Many neurologic conditions create a difference in fluid volumes between the brain's right and left hemispheres.

The device detects that fluid asymmetry as a change in the ratio of bioimpedance measurements on each of the two sides.

The company has developed a proprietary machine learning system to optimize its algorithms to recognize